JP2005531559A - 組織ダメージの治療と予防 - Google Patents

組織ダメージの治療と予防 Download PDF

Info

Publication number
JP2005531559A
JP2005531559A JP2004505099A JP2004505099A JP2005531559A JP 2005531559 A JP2005531559 A JP 2005531559A JP 2004505099 A JP2004505099 A JP 2004505099A JP 2004505099 A JP2004505099 A JP 2004505099A JP 2005531559 A JP2005531559 A JP 2005531559A
Authority
JP
Japan
Prior art keywords
crp
ligand
drug according
binding
ligands
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2004505099A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005531559A5 (cg-RX-API-DMAC10.html
Inventor
マーク ビー ペピィズ
スティーヴン ヴィクター レイ
アレキサンダー ジョン アンドレ コッブ
Original Assignee
ペントラキシン セラピューティクス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ペントラキシン セラピューティクス リミテッド filed Critical ペントラキシン セラピューティクス リミテッド
Publication of JP2005531559A publication Critical patent/JP2005531559A/ja
Publication of JP2005531559A5 publication Critical patent/JP2005531559A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
JP2004505099A 2002-05-15 2003-05-14 組織ダメージの治療と予防 Ceased JP2005531559A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0211136.7A GB0211136D0 (en) 2002-05-15 2002-05-15 Treatment and prevention of tissue damage
PCT/GB2003/002096 WO2003097104A1 (en) 2002-05-15 2003-05-14 Treatment and prevention of tissue damage

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010022669A Division JP2010174013A (ja) 2002-05-15 2010-02-04 組織ダメージの治療と予防

Publications (2)

Publication Number Publication Date
JP2005531559A true JP2005531559A (ja) 2005-10-20
JP2005531559A5 JP2005531559A5 (cg-RX-API-DMAC10.html) 2011-03-31

Family

ID=9936726

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004505099A Ceased JP2005531559A (ja) 2002-05-15 2003-05-14 組織ダメージの治療と予防
JP2010022669A Pending JP2010174013A (ja) 2002-05-15 2010-02-04 組織ダメージの治療と予防

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010022669A Pending JP2010174013A (ja) 2002-05-15 2010-02-04 組織ダメージの治療と予防

Country Status (11)

Country Link
US (1) US7615543B2 (cg-RX-API-DMAC10.html)
EP (1) EP1503800B1 (cg-RX-API-DMAC10.html)
JP (2) JP2005531559A (cg-RX-API-DMAC10.html)
AT (1) ATE446761T1 (cg-RX-API-DMAC10.html)
AU (1) AU2003234000B8 (cg-RX-API-DMAC10.html)
CA (1) CA2485852C (cg-RX-API-DMAC10.html)
DE (1) DE60329839D1 (cg-RX-API-DMAC10.html)
DK (1) DK1503800T3 (cg-RX-API-DMAC10.html)
ES (1) ES2333522T3 (cg-RX-API-DMAC10.html)
GB (1) GB0211136D0 (cg-RX-API-DMAC10.html)
WO (1) WO2003097104A1 (cg-RX-API-DMAC10.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010174013A (ja) * 2002-05-15 2010-08-12 Pentraxin Therapeutics Ltd 組織ダメージの治療と予防
KR20170020842A (ko) * 2014-06-19 2017-02-24 펜트라코르 게엠베하 포스포릴 콜린 유도체를 포함하는 분리 재료
JP2023529047A (ja) * 2020-02-19 2023-07-07 ユーシーエル・ビジネス・リミテッド 組織損傷の治療に使用するための作用剤

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05001202A (es) 2002-07-29 2005-11-23 Hawaii Biotech Inc Analogos carotenoides estructurales para la inhibicion y mejora de la enfermedad.
US8012472B2 (en) 2002-12-23 2011-09-06 William Marsh Rice University Compositions and methods for suppressing fibrocytes
JP4922560B2 (ja) 2002-12-23 2012-04-25 ウイリアム、マーシュ、ライス、ユーニヴァーサティ 線維細胞への分化の検出方法、線維症を抑制する組成物および方法
US7763256B2 (en) 2002-12-23 2010-07-27 William Marsh Rice University Compositions and methods for suppressing fibrocytes and for detecting fibrocyte differentiation
GB0313386D0 (en) * 2003-06-10 2003-07-16 Univ London Treatment of disease
US20070265196A1 (en) * 2004-01-21 2007-11-15 Medvet Science Pty., Ltd. Method of Modulating Pro-Inflammatory and Inflammatory Activity Mediated by C-Reactive Protein
EP1582527A1 (en) * 2004-03-31 2005-10-05 Ciba SC Holding AG Synthesis of phosphorus based ligands
EP1893227A2 (en) 2005-06-06 2008-03-05 Girish J. Kotwal Methods for treatment or prophylaxis of atherosclerosis and reperfusion injury
JP5220025B2 (ja) 2006-12-04 2013-06-26 プロメディオール, インコーポレイテッド 線維症疾患を処置するための併用療法
US9884899B2 (en) 2007-07-06 2018-02-06 Promedior, Inc. Methods for treating fibrosis using CRP antagonists
US8497243B2 (en) 2007-07-06 2013-07-30 Promedior, Inc. Methods and compositions useful in the treatment of mucositis
PT2405928T (pt) 2009-03-11 2017-02-07 Promedior Inc Métodos de tratamento e de diagnóstico para patologias de hipersensibilidade
PT2405929T (pt) 2009-03-11 2018-07-23 Promedior Inc Métodos de tratamento para distúrbios autoimunes
UA110323C2 (en) 2009-06-04 2015-12-25 Promedior Inc Derivative of serum amyloid p and their receipt and application
HUE041034T2 (hu) 2009-06-17 2019-05-28 Promedior Inc SAP-variánsok és alkalmazásuk
WO2011034776A1 (en) 2009-09-18 2011-03-24 Dow Global Technologies Inc. Powdered thermoplastic polyolefin elastomer composition for slush molding processes
EP2580278B1 (en) 2010-06-08 2014-10-29 Dow Global Technologies LLC Polyolefin elastomer composition for artificial leather applications
EP2790690A4 (en) * 2011-12-14 2015-08-12 Texas A & M Univ Sys COMPOSITIONS AND METHODS OF MANAGING NEUTROPHILIC MOVEMENTS USING THE SERUM AMYLOID P (SAP)
WO2014036473A1 (en) 2012-08-31 2014-03-06 Kenji Suzuki Supervised machine learning technique for reduction of radiation dose in computed tomography imaging
WO2021197371A1 (zh) * 2020-03-31 2021-10-07 南京金斯瑞生物科技有限公司 一种含有刚性连接子的生物偶联物
WO2022178594A1 (en) * 2021-02-25 2022-09-01 Baker Heart and Diabetes Institute C-reactive protein inhibitors
GB202111866D0 (en) 2021-08-18 2021-09-29 Ucl Business Plc Prodrugs for use in the treatment of tissue damage
KR20230060368A (ko) * 2021-10-27 2023-05-04 솔브레인 주식회사 환형 포스핀 화합물의 제조방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4640913A (en) 1983-01-10 1987-02-03 American Cyanamid Company Phosphocholine derivatives having antihypertensive action
IL84252A (en) 1987-10-23 1994-02-27 Yissum Res Dev Co Phospholipase inhibiting compositions
US5681829A (en) 1992-10-08 1997-10-28 Shaman Pharmaceuticals, Inc. Class of phosphocholine derivatives having antifungal activity
US5811568A (en) 1992-10-08 1998-09-22 Shaman Pharmaceuticals, Inc. Process for the preparation of mono- and bis(phosphocholine) derivatives which have antifungal activity
JP4524846B2 (ja) 2000-04-20 2010-08-18 日油株式会社 化粧料
JP2003536075A (ja) 2000-06-08 2003-12-02 ボード・オブ・リージェンツ,ザ・ユニヴァーシティ・オヴ・テキサス・システム C反応性タンパク質誘導性炎症のインヒビター
US7390795B2 (en) * 2000-12-18 2008-06-24 Pentraxin Therapeutics Limited Treatment and prevention of tissue damage
DE60219926T2 (de) * 2001-08-08 2007-11-22 Pentraxin Therapeutics Ltd. Wirkstoff zur entfernung einer unerwünschten proteinpopulation aus dem plasma
GB0211136D0 (en) * 2002-05-15 2002-06-26 Univ London Treatment and prevention of tissue damage

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN7009003665, CHRISTNER,R.B. et al, "Binding of human serum amyloid P−component to phosphocholine", Arch Biochem Biophys, 1994, Vol.314, No.2, p.337−43 *
JPN7009003666, LU,Q. et al, "Synthetic analogues of irlbacholine: a novel antifungal plant metabolite isolated from Irlbachia ala", J Nat Prod, 1999, Vol.62, No.6, p.824−8 *
JPN7009003671, LIUZZO,G. et al, "The prognostic value of C−reactive protein and serum amyloid a protein in severe unstable angina", N Engl J Med, 1994, Vol.331, No.7, p.417−24 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010174013A (ja) * 2002-05-15 2010-08-12 Pentraxin Therapeutics Ltd 組織ダメージの治療と予防
KR20170020842A (ko) * 2014-06-19 2017-02-24 펜트라코르 게엠베하 포스포릴 콜린 유도체를 포함하는 분리 재료
JP2017526732A (ja) * 2014-06-19 2017-09-14 ペントラコール ゲーエムベーハー ホスホリルコリン誘導体を含む分離物質
KR101971958B1 (ko) * 2014-06-19 2019-04-24 펜트라코르 게엠베하 포스포릴 콜린 유도체를 포함하는 분리 재료
JP2023529047A (ja) * 2020-02-19 2023-07-07 ユーシーエル・ビジネス・リミテッド 組織損傷の治療に使用するための作用剤
JP2023534884A (ja) * 2020-02-19 2023-08-15 ユーシーエル・ビジネス・リミテッド 組織損傷の治療に使用するための作用剤2
JP7828285B2 (ja) 2020-02-19 2026-03-11 ユーシーエル・ビジネス・リミテッド 組織損傷の治療に使用するための作用剤2

Also Published As

Publication number Publication date
CA2485852C (en) 2012-01-17
ES2333522T3 (es) 2010-02-23
EP1503800A1 (en) 2005-02-09
WO2003097104A1 (en) 2003-11-27
US20060019930A1 (en) 2006-01-26
AU2003234000A1 (en) 2003-12-02
DE60329839D1 (de) 2009-12-10
JP2010174013A (ja) 2010-08-12
DK1503800T3 (da) 2010-02-01
EP1503800B1 (en) 2009-10-28
GB0211136D0 (en) 2002-06-26
AU2003234000B8 (en) 2008-07-31
AU2003234000B2 (en) 2008-06-05
CA2485852A1 (en) 2003-11-27
US7615543B2 (en) 2009-11-10
ATE446761T1 (de) 2009-11-15

Similar Documents

Publication Publication Date Title
CA2485852C (en) Agent for binding a plurality of c-reactive protein and their use in the treatment and prevention of tissue damage
JP2005531559A5 (cg-RX-API-DMAC10.html)
JP5597543B2 (ja) 糖衣の幅を決定する方法およびプログラム
Zhang et al. Desmin-and vimentin-mediated hepatic stellate cell-targeting radiotracer 99mTc-GlcNAc-PEI for liver fibrosis imaging with SPECT
JP5998171B2 (ja) 心臓障害を検出するための方法
US8039222B2 (en) Treatment and prevention of tissue damage
KR102362358B1 (ko) 치료제 및 이의 용도
US9575074B2 (en) Method for evaluating atherosclerotic lesion, and kit
US20090311182A1 (en) Macromolecular Delivery Systems for Non-Invasive Imaging, Evaluation and Treatment of Arthritis and Other Inflammatory Diseases
Abou-Elkacem et al. Ultrasound molecular imaging of the breast cancer neovasculature using engineered fibronectin scaffold ligands: a novel class of targeted contrast ultrasound agent
Stoger et al. Macrophage heterogeneity: relevance and functional implications in atherosclerosis
AU2005203633B2 (en) Peptide-based carrier devices for stellate cells
JP5055438B2 (ja) ホスファチジルセリンと特異的に結合するポリペプチド及びこれの用途
US20150218273A1 (en) Oncofetal antigen/immature laminin receptor antibodies for diagnostic and clinical applications
WO2021170782A2 (en) Epi-x4 based peptides and derivatives thereof
JP2023522984A (ja) 重症急性呼吸促迫症候群の処置のためのデンドリマー組成物および方法
WO2025098478A1 (zh) 一种全过程靶向多肽、其药物复合物、递药系统及其应用
Riou et al. Pre-clinical and clinical evaluation of nuclear tracers for the molecular imaging of vulnerable atherosclerosis: an overview
US7943775B2 (en) Small molecules for imaging protein-protein interactions
US20240299358A1 (en) Compositions and methods for diagnosis and treatment of autoimmune diseases
US20250387497A1 (en) Multivalent multispecific conjugates and related compositions and methods of use
JP2019509298A (ja) インビボでの切断可能連結部分によって抗マトリプターゼ抗体にコンジュゲートされた化学療法剤を用いる腫瘍細胞の標的化
WO2021195465A1 (en) Treatment of acute respiratory distress syndrome and related conditions with antagonists of e-selectin
WO2025047727A1 (ja) D型ペプチド及びその用途
Moldovan et al. Role of Heat Shock Factor-1 Activation in the Doxorubicin-induced 2 Heart Failure in Mice 3

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20050726

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20050726

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060511

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070320

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20070320

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090804

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091102

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091110

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091204

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091211

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100204

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20100204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100215

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20100215

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100810

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101104

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101111

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20110210

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110308

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110602

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110609

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20111011

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120210

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20120417

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120515

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20120925